# Metabolic Checkpoints in CD8+ T Cells within the Tumor Microenvironment: A Comprehensive Review and Emerging Insights

**Authors:** Jiaqi Ai, Yiheng Du, Qianqian Xue, Wenbei Peng, Qiong Zhou

PMC · DOI: 10.7150/ijbs.125206 · International Journal of Biological Sciences · 2026-01-22

## TL;DR

This review explores how metabolism in CD8+ T cells affects their ability to fight cancer and how targeting metabolic checkpoints could improve cancer treatments.

## Contribution

The paper provides a comprehensive analysis of how metabolic checkpoints influence CD8+ T cell function and anti-tumor immunity.

## Key findings

- Metabolic reprogramming in CD8+ T cells is crucial for their anti-tumor activity within the tumor microenvironment.
- Key metabolites and metabolic checkpoints regulate CD8+ T cell differentiation and immune responses through glucose, lipid, and amino acid metabolism.
- Heterogeneity in the effects of metabolic checkpoints on CD8+ T cells suggests potential for targeted clinical applications.

## Abstract

In recent years, a growing number of evidence suggests that cancer is a metabolic disease. Metabolic reprogramming is a hallmark of the TME, where various nutrients, including glucose, lipids, and amino acids, play key roles in regulating tumor development by acting on both tumor cells and immune cells. T cells are the core mediators of anti-tumor immunity. Especially CD8+ T cells are considered the primary immune cells involved in the anti-tumor immune response. Upon stimulation by tumor antigens and other immune cells, CD8+ T cells undergo metabolic reprogramming through signaling pathways. Metabolites or metabolic checkpoints induce epigenetic changes in key genes, altering the differentiation and effector function of CD8+ T cells. This review first elaborates on the anti-tumor functional characteristics and metabolic profiles of CD8+ T cells at different stages of differentiation in the TME. Then we focus on the roles of key metabolites and metabolic checkpoints in shaping CD8+ T cell differentiation, functionality, and immune responses, specifically through glucose, lipid, and amino acid metabolism. Finally, we discuss the reasons for heterogeneity in the effects of metabolic checkpoints on CD8+ T cells and explore potential clinical applications of metabolic checkpoints in treatment. Understanding the correlation between CD8+ T cell metabolism and anti-tumor immunotherapy may facilitate the development of new strategies to enhance the efficacy of CD8+ T cell-based cancer treatments.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}
- **Diseases:** metabolic disease (MESH:D008659), Tumor (MESH:D009369)
- **Chemicals:** lipid (MESH:D008055), glucose (MESH:D005947), amino acid (MESH:D000596)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12905573/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12905573/full.md

## References

174 references — full list in the complete paper: https://tomesphere.com/paper/PMC12905573/full.md

---
Source: https://tomesphere.com/paper/PMC12905573